ES2187946T3 - Uso de interleucina-15. - Google Patents

Uso de interleucina-15.

Info

Publication number
ES2187946T3
ES2187946T3 ES98912417T ES98912417T ES2187946T3 ES 2187946 T3 ES2187946 T3 ES 2187946T3 ES 98912417 T ES98912417 T ES 98912417T ES 98912417 T ES98912417 T ES 98912417T ES 2187946 T3 ES2187946 T3 ES 2187946T3
Authority
ES
Spain
Prior art keywords
antibodies
alpha
inhibiting
compounds
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98912417T
Other languages
English (en)
Inventor
Johan Adriaan Marc Grooten
Hans Peter Raf Dooms
Walter Charles Fiers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187946(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Application granted granted Critical
Publication of ES2187946T3 publication Critical patent/ES2187946T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a la utilización de la IL-15 o de variantes activos de la misma y/o compuestos mejoradores de la actividad de la IL-15 para la fabricación de una composición farmacéutica para manipular las células memoria del sistema inmune, tal como para manipular la viabilidad y/o la sensibilidad de las células memoria. El compuesto mejorador de la actividad de la IL-15 es por ejemplo un lipopolisacárido (LPS). La invención se refiere además a la utilización de compuestos que inhiben o eliminan la actividad de la IL-15 para la fabricación de una composición farmacéutica para manipular las células memoria del sistema inmune. Los compuestos de inhibición o eliminación son por ejemplo anticuerpos anti-IL-15, anticuerpos anti-IL- 15R{sub,alfa}, fragmentos de estos anticuerpos, por ejemplo el fragmento Fab o F(ab¿){sub,2}, IL-15-R{sub,alfa}soluble, proteínas de fusión que constan de IL-15R{sub,alfa} y del fragmento Fc, compuestos, por ejemplo péptidos, que se unen y/o inhiben el receptor funcional de la IL-15, oligonucleótidos antisentido IL-15.
ES98912417T 1997-02-21 1998-02-23 Uso de interleucina-15. Expired - Lifetime ES2187946T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200515 1997-02-21

Publications (1)

Publication Number Publication Date
ES2187946T3 true ES2187946T3 (es) 2003-06-16

Family

ID=8228040

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98912417T Expired - Lifetime ES2187946T3 (es) 1997-02-21 1998-02-23 Uso de interleucina-15.

Country Status (9)

Country Link
US (3) US6344192B1 (es)
EP (2) EP0971728B1 (es)
AT (2) ATE229342T1 (es)
AU (1) AU6726698A (es)
DE (2) DE69830257T3 (es)
DK (1) DK1273304T4 (es)
ES (1) ES2187946T3 (es)
WO (1) WO1998036768A1 (es)
ZA (1) ZA981478B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
EP1927657A3 (en) * 2000-05-11 2008-10-22 Baylor Research Institute Compositions and methods for producing antigen-presenting cells
RU2280255C2 (ru) * 2000-09-14 2006-07-20 Бет Изрейэл Диконисс Медикал Сентер, Инк. Модуляция il-2- и il-15-опосредованных т-клеточных ответов
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
EA014802B1 (ru) 2001-08-23 2011-02-28 Генмаб А/С АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
US8007813B2 (en) 2003-03-26 2011-08-30 Apogenix Gmbh CD95-Fc fusion proteins
WO2005014642A2 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
EP1809321B1 (en) 2004-10-08 2012-03-14 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Adoptive immunotherapy with enhanced t lymphocyte survival
PT1899364T (pt) 2005-05-17 2020-05-20 Univ Connecticut Composições e métodos para imunomodulação num organismo
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
AU2007207785B2 (en) 2006-01-13 2013-11-14 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL- 15 and IL- 15R-alpha genes for expression in mammalian cells
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
ES2470772T3 (es) 2007-05-11 2014-06-24 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP4385570A3 (en) 2010-09-21 2024-09-11 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
CA3151221A1 (en) 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
WO1996015808A1 (en) * 1994-11-17 1996-05-30 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
EP0855918A4 (en) * 1995-10-17 2002-08-14 Univ Wayne State INTERLEUKIN-15 FROM CHICKEN AND USES THEREOF
US5870759A (en) * 1996-10-09 1999-02-09 Oracle Corporation System for synchronizing data between computers using a before-image of data
US6065018A (en) * 1998-03-04 2000-05-16 International Business Machines Corporation Synchronizing recovery log having time stamp to a remote site for disaster recovery of a primary database having related hierarchial and relational databases
US6356917B1 (en) * 1998-07-17 2002-03-12 Ncr Corporation Monitoring and raising alerts for database jobs
US6553392B1 (en) * 1999-02-04 2003-04-22 Hewlett-Packard Development Company, L.P. System and method for purging database update image files after completion of associated transactions
US6728879B1 (en) * 1999-06-02 2004-04-27 Microsoft Corporation Transactional log with multi-sector log block validation

Also Published As

Publication number Publication date
EP0971728A1 (en) 2000-01-19
US20020182178A1 (en) 2002-12-05
US6344192B1 (en) 2002-02-05
DE69810091T2 (de) 2003-10-09
EP1273304B2 (en) 2009-07-15
ATE295736T1 (de) 2005-06-15
EP1273304B1 (en) 2005-05-18
EP1273304A2 (en) 2003-01-08
DE69830257T2 (de) 2006-02-02
US20070134718A1 (en) 2007-06-14
EP0971728B1 (en) 2002-12-11
EP1273304A3 (en) 2003-04-23
DE69830257D1 (de) 2005-06-23
WO1998036768A1 (en) 1998-08-27
DK1273304T4 (da) 2009-08-31
ATE229342T1 (de) 2002-12-15
DK1273304T3 (da) 2005-09-12
DE69810091D1 (de) 2003-01-23
AU6726698A (en) 1998-09-09
ZA981478B (en) 1998-08-24
DE69830257T3 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
ES2187946T3 (es) Uso de interleucina-15.
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NL300220I1 (nl) Immunoglobuline varianten voor specifieke FC-epsilon receptoren.
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
RS20130234A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
PT1331944E (pt) Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28
ATE542138T1 (de) Her-2-bindungsantagonisten
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ES2129120T3 (es) Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g.
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
NZ237533A (en) Monoclonal antibodies which bind to oncostatin m, cell lines producing them
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
AU2002323894A1 (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
MX9704225A (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora.